Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors
Sukhmani Kaur Padda, Jonathan Wesley Riess, Erich Schwartz et al. · Journal of Thoracic Oncology · 2014
Cited by 156 works. doi:10.1097/jto.0000000000000429
Authors
- Sukhmani Kaur Padda
- Jonathan Wesley Riess
- Erich Schwartz
- Lü Tian
- Holbrook E K Kohrt
- Joel W. Neal
- Robert B. West
- Heather A. Wakelee
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Tissue microarrays for high-throughput molecular profiling of tumor specimens
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy